Double‐blind trial of recombinant γ‐interferon versus placebo in the treatment of rheumatoid arthritis | Zendy

Grant W Can | Zendy; Seth H Pincus | Zendy; Ronald D Emkey | Zendy; Alex Denes | Zendy; Selwyn A Cohen | Zendy; Frederick Wolfe | Zendy; P Anthony Saway | Zendy; Adrian M Jaffer | Zendy; Arthur L Weaver | Zendy; Lewis Cogen | Zendy; John D Schindler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Double‐blind trial of recombinant γ‐interferon versus placebo in the treatment of rheumatoid arthritis

Author(s) -

Grant W Can,

Seth H Pincus,

Ronald D Emkey,

Alex Denes,

Selwyn A Cohen,

Frederick Wolfe,

P Anthony Saway,

Adrian M Jaffer,

Arthur L Weaver,

Lewis Cogen,

John D Schindler

Publication year - 2008

Publication title -

arthritis & rheumatism

Language(s) - English

Resource type - Journals

eISSN - 1529-0131

pISSN - 0004-3591

DOI - 10.1002/art.23361

Subject(s) - rheumatoid arthritis , placebo , medicine , arthritis , rheumatism , physical therapy , double blind , recombinant dna , placebo group , alternative medicine , pathology , biochemistry , chemistry , gene

One hundred five patients were enrolled in a 12-week, randomized, prospective, double-blind, placebo-controlled trial of recombinant human gamma-interferon (rHu gamma-IFN) for the treatment of rheumatoid arthritis. Fifty-four patients received rHu gamma-IFN and 51 received placebo. Forty-two patients in each group completed the 12-week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHu gamma-IFN was greater than that with placebo, the differences were generally not statistically significant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research